Joining ICH, China FDA embraces global community of regulators

10 August 2017

The China Food and Drug Administration (CFDA) has been accepted as a member of the ICH, the global federation of regulators that seeks to harmonize health technology regulations.

Founded in 1990, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) issues guidelines for regulators “via a process of scientific consensus, with regulatory and industry experts working side-by-side.”

ICH Guidelines, which may relate to the quality, safety or efficacy of medicines, set the agenda for Good Manufacturing Practice (GMP), as well as the design, conduct, safety and reporting of clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK